OBJECTIVES: The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. METHODS: A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. RESULTS: The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). CONCLUSIONS: A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively.

Department of Applied Pharmacy Faculty of Pharmacy Masaryk University Brno Czech Republic

Department of Clinical Pharmacy Military University Hospital Prague Prague Czech Republic

Department of Infectious Diseases 1st Faculty of Medicine Charles University and Military University Hospital Prague Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Laboratory of Pharmacology and Toxicology AGEL Laboratories Nový Jičín Czech Republic

Zobrazit více v PubMed

Papp-Wallace KM, Endimiani A, Taracila MA, et al. . Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011;55:4943–60. 10.1128/AAC.00296-11 PubMed DOI PMC

Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 1997;24 Suppl 2:S266–75. 10.1093/clinids/24.Supplement_2.S266 PubMed DOI

Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255–71. 10.1016/j.ccc.2006.02.011 PubMed DOI

Wong G, Briscoe S, McWhinney B, et al. . Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother 2018;73:3087–94. 10.1093/jac/dky314 PubMed DOI

Scharf C, Liebchen U, Paal M, et al. . The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. J Intensive Care 2020;8:86. 10.1186/s40560-020-00504-w PubMed DOI PMC

European Committee on Antimicrobial Susceptibility Testing . Clinical breakpoints - breakpoints and guidance. Available: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf [Accessed 11 Oct 2022].

Bradley JS, Garau J, Lode H, et al. . Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999;11:93–100. 10.1016/S0924-8579(98)00094-6 PubMed DOI

Lansbury L, Lim B, Baskaran V, et al. . Co-Infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81:266–75. 10.1016/j.jinf.2020.05.046 PubMed DOI PMC

Rawson TM, Moore LSP, Zhu N, et al. . Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–68. 10.1093/cid/ciaa530 PubMed DOI PMC

Goncalves-Pereira J, Silva NE, Mateus A, et al. . Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol 2014;15:21. 10.1186/2050-6511-15-21 PubMed DOI PMC

McClelland S, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis 2007;45:55–9. 10.1086/518580 PubMed DOI

Schneider F, Gessner A, El-Najjar N. Efficacy of vancomycin and meropenem in central nervous system infections in children and adults: current update. Antibiotics 2022;11:173. 10.3390/antibiotics11020173 PubMed DOI PMC

Almalki MH, Ahmad MM, Brema I, et al. . Management of diabetes insipidus following surgery for pituitary and suprasellar tumours. Sultan Qaboos Univ Med J 2021;21:354–64. 10.18295/squmj.4.2021.010 PubMed DOI PMC

Yu Z, Pang X, Wu X, et al. . Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One 2018;13:e0201667. 10.1371/journal.pone.0201667 PubMed DOI PMC

Truong AQ, Dao XC, Vu DH, et al. . Optimizing meropenem in highly resistant Klebsiella pneumoniae environments: population pharmacokinetics and dosing simulations in critically ill patients. Antimicrob Agents Chemother 2022:e0032122. 10.1128/aac.00321-22 PubMed DOI PMC

Thémans P, Marquet P, Winkin JJ, et al. . Towards a generic tool for prediction of meropenem systemic and infection-site exposure: a physiologically based pharmacokinetic model for adult patients with pneumonia. Drugs R D 2019;19:177–89. 10.1007/s40268-019-0268-x PubMed DOI PMC